Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?
about
Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactionsComparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patientsPredictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.Genetic variants in the apoptosis gene BCL2L1 improve response to interferon-based treatment of hepatitis C virus genotype 3 infection.Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictorsIL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC StudyRecent advances in management of the HIV/HCV coinfected patient.IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based testA survey of hepatitis C treatment clinical practice patterns using the newly approved protease inhibitors.Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C.Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis CMany patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities.Impact of biomarkers on clinical trial risk.Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes.Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection.Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population.The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients.IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients.
P2860
Q27014831-94CCA93F-A6E6-4EA9-81E9-C3B0EA58E082Q33411348-32665F9F-2884-489F-941C-F231DC8DB3E3Q33596086-61C23DC0-8A65-41B1-8B51-AE30368C5430Q33944295-5BA31B78-288E-493B-96F6-F63E237450AFQ34057340-BD364B96-AC26-400C-97D1-7BCAE4ABB48BQ34114361-C55B55E5-EB00-461E-A455-869A3A775F42Q35139010-03FA4161-50B6-4D41-81F3-F95DF6193BF6Q35146790-A1FE7725-DC38-4073-9C5D-6796697E21B8Q35855775-A8521203-A5E1-41FE-8D36-99F0ACFBACCAQ35869247-073A4046-3DBA-4604-A984-C5A0E8687491Q36575497-C06D3596-2BAC-493A-8D0B-CEED0745BC17Q36836988-4C3F66CD-A9C8-48F8-A959-B88074B63E3FQ37067537-D489B2E4-FA77-4100-95E8-996081BDA8AAQ37093573-0AA11029-80A2-4F27-B49D-A6F48E11A91DQ37651899-57827F8B-B4EC-48D1-AB59-A4213F2A7180Q37678082-83E6DB8F-BC98-4614-844E-9E426D717802Q38148601-D73AB3E3-D9AD-4FDB-9211-7D7C9EEC3D22Q38926063-21622C89-8666-46F1-85FA-720B217D955AQ41545630-641B163C-0A76-4629-8A9C-6479E79925BCQ42217800-DD2EF1DE-133E-429B-9B7B-9A6A10F6537EQ42250948-DE62CC4C-70A4-4F10-96F4-EADDD581C941Q42269830-60053835-4FA6-484C-B58C-B1692FABFB2BQ54263185-4A8547FA-4503-4EB4-BE95-1CA36606C1E1
P2860
Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Does IL28B genotyping still ha ...... chronic hepatitis C infection?
@en
type
label
Does IL28B genotyping still ha ...... chronic hepatitis C infection?
@en
prefLabel
Does IL28B genotyping still ha ...... chronic hepatitis C infection?
@en
P2093
P2860
P356
P1476
Does IL28B genotyping still ha ...... chronic hepatitis C infection?
@en
P2093
A J Thompson
J A Holmes
P V Desmond
P2860
P304
P356
10.1111/JVH.12003
P577
2012-10-01T00:00:00Z